Role of Prior Authorization in Accessing Anti-VEGF Therapies in Retinal Vascular Diseases

In this episode, “Role of Prior Authorization in Accessing Anti-VEGF Therapies in Retinal Vascular Diseases,” the panelists explore how prior authorization requirements may influence access to anti-VEGF therapies for patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The expert faculty discuss the intended role of utilization management strategies while also examining whether current prior authorization processes effectively balance cost stewardship, administrative burden, and timely patient care.

During the discussion, the panel reviews data suggesting that prior authorization approval rates for retina therapies are already very high, raising questions about whether current processes meaningfully alter prescribing behavior or primarily create delays and additional administrative workload. The expert faculty also examine how current authorization systems may consume resources across both physician practices and payer organizations without consistently improving utilization outcomes.

The panel highlights opportunities for more targeted and data-driven approaches to utilization management, including the possibility of incorporating disease-specific imaging, phenotypic outcomes, and provider-level prescribing patterns into authorization strategies. The discussion also emphasizes the importance of reducing non-value-added administrative activities that may contribute to treatment delays in vision-threatening retinal diseases.

In addition, the expert faculty discuss the need for stronger collaboration between payers and retina specialists to develop more sustainable access pathways that support both appropriate treatment utilization and patient outcomes. Throughout the episode, the panel emphasizes that improving communication between healthcare stakeholders may help reduce friction in the treatment process while maintaining responsible management of healthcare costs.

The next episode in this series, “Physician Choice and Step Therapy in Retinal Vascular Diseases,” features the panelists discussing how formulary restrictions and step therapy requirements may affect treatment sequencing, healthcare costs, and long-term patient outcomes. The panel also highlights the importance of collaboration between payers and retina specialists to support clinically appropriate and sustainable access strategies.